PureTech Health Doses First Patient In Phase 1 LYT-100 Study
PureTech Health Doses First Patient In Phase 1 LYT-100 Study
Read moreTue, 18th Dec 2018 11:09
PureTech Health Doses First Patient In Phase 1 LYT-100 Study
Read more(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health announced on Tuesday that the first participant has been dosed in a clinical study of 'LYT-100', its wholly-owned product candidate for the potential treatment of lymphoedema and other fibrotic conditions.
Read morePureTech Health Affiliate Akili Posts Encouraging ADHD Study Results
Read more(Sharecast News) - TT Electronics: Jefferies downgrades to hold with a target price of 265p.
Read more(Sharecast News) - Clinical stage biotech company PureTech Health said it had sold 2.1m shares of its affiliate Karuna Therapeutics for $200m.
Read morePureTech Health Unit Akili's AKL-T01 Study Achieves Primary Endpoint
Read morePureTech Health Affiliate Reports Positive Results In Alopecia Study
Read more(Sharecast News) - PureTech Health on Thursday said results from a study into a hair loss treatment developed by its affiliate Follica demonstrated a statistically significant 44% improvement in hair count.
Read morePureTech's Gelesis Partners With Telehealth Firm Ro For Plenity In US
Read morePureTech Health Investee Akili Delivers Positive AKL-T03 Trial Results
Read morePureTech Health's Vedanta Launches First-In-Patient Study Of VE800
Read morePureTech Health Investee Gelesis Gets USD85 Million For Plenity Launch
Read more(Sharecast News) - Biotechnology commercialisation company PureTech Health noted on Monday that its affiliate Gelesis had secured $84.6m (£64.26m) in new capital.
Read morePureTech Affiliate Vedanta Gets USD6 Million Grant For VE707 Programme
Read more(Sharecast News) - Clinical stage biotechnology company PureTech Health said on Thursday that its affiliate, Vedanta Biosciences, has been awarded a $5.8m grant for its 'VE707' programme, targeting multidrug resistant infections.
Read more